Elenestinib
BLU-263-1201
Phase 3 small_molecule active
Quick answer
Elenestinib for Indolent Systemic Mastocytosis is a Phase 3 program (small_molecule) at Blueprint Medicines (Netherlands) B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Blueprint Medicines (Netherlands) B.V.
- Indication
- Indolent Systemic Mastocytosis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active